Microbiology Quiz: Immunological Memory And Vaccination
20 questions · exam conditions
0:00
Immunological Memory And VaccinationQuestion 1 of 20

An elderly patient with a history of chickenpox (varicella-zoster virus, VZV) in childhood develops shingles. This condition is caused by the reactivation of the latent VZV. Which concept of immunological memory does this clinical scenario best illustrate?

The complete failure of the immune system to generate any memory B or T cells against VZV during the primary infection.
The phenomenon of original antigenic sin, where memory from the primary infection inhibits a response to the reactivated virus.
The generation of non-protective antibodies that enhance viral replication upon secondary exposure.
A decline in the frequency and/or function of VZV-specific memory T cells below a protective threshold, allowing viral reactivation.
← Back to quizzes

Microbiology Quiz

Microbiology Quiz: Immunological Memory And Vaccination

Practice Immunological Memory And Vaccination in Microbiology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Immunological Memory And Vaccination, giving you a quick way to practice the rules, question types, and explanations that matter most for Microbiology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

An elderly patient with a history of chickenpox (varicella-zoster virus, VZV) in childhood develops shingles. This condition is caused by the reactivation of the latent VZV. Which concept of immunological memory does this clinical scenario best illustrate?

  1. The complete failure of the immune system to generate any memory B or T cells against VZV during the primary infection.
  2. The phenomenon of original antigenic sin, where memory from the primary infection inhibits a response to the reactivated virus.
  3. The generation of non-protective antibodies that enhance viral replication upon secondary exposure.
  4. A decline in the frequency and/or function of VZV-specific memory T cells below a protective threshold, allowing viral reactivation. (correct answer)
Explanation: When you encounter questions about viral reactivation and immunological memory, focus on understanding how immune protection can wane over time rather than completely disappear. Shingles (herpes zoster) represents a classic example of how immunological memory can decline with age. After childhood chickenpox, varicella-zoster virus establishes latency in your nerve cells. Your immune system doesn't eliminate the virus entirely but keeps it suppressed through ongoing T cell surveillance. As you age, the frequency and effectiveness of VZV-specific memory T cells gradually decline. When this cellular immunity drops below a critical protective threshold, the dormant virus can reactivate and cause shingles. Option A is incorrect because the immune system does generate robust memory responses during primary VZV infection—this is why most people don't get chickenpox twice. Option B misapplies original antigenic sin, which refers to preferential immune responses to previously encountered antigens rather than newer variants of the same pathogen. This doesn't explain why reactivation occurs from the same virus strain. Option C describes antibody-dependent enhancement, a phenomenon seen with some viruses like dengue, but VZV reactivation isn't caused by enhancing antibodies—it's primarily a T cell-mediated immunity issue. The correct answer is D because it accurately describes immunosenescence—the age-related decline in immune function that allows latent viruses to reactivate. Study tip: Remember that latent viral reactivations (VZV, HSV, CMV) typically result from weakened T cell immunity over time, not from absent memory or harmful antibodies. This concept frequently appears on microbiology exams.

Question 2

Following recovery from a resolved acute viral infection, which population of memory T cells is primarily responsible for long-term surveillance by circulating through secondary lymphoid organs and initiating a rapid proliferative response upon secondary exposure?

  1. Effector memory T cells (Tₑₘ) located in peripheral non-lymphoid tissues.
  2. Tissue-resident memory T cells (Tₑₘ) that remain at the site of the initial infection.
  3. Central memory T cells (Tₑₘ) that express CCR7 and L-selectin. (correct answer)
  4. Recently activated effector T cells that have not yet undergone contraction.
Explanation: Immunological memory in the T-cell compartment is maintained by distinct subsets. Central memory T cells (TCM) are characterized by their expression of the lymph node homing receptors CCR7 and L-selectin (CD62L). This allows them to reside in and recirculate between secondary lymphoid organs (like lymph nodes and spleen). Upon re-encountering their cognate antigen, they exhibit a high proliferative capacity, rapidly expanding to generate a large pool of new effector cells. A: Effector memory T cells (TEM) lack CCR7 and circulate through peripheral tissues, poised for immediate effector function rather than proliferation in lymph nodes. B: Tissue-resident memory T cells (TRM) are non-circulating and provide a first line of defense at barrier surfaces. D: Recently activated effector T cells are part of the primary response and most will die by apoptosis during the contraction phase; they are not the long-lived memory population.

Question 3

An individual receives an mRNA vaccine against a viral pathogen. The vaccine lipid nanoparticle delivers mRNA encoding the viral spike protein into host cells.

Which of the following describes the key pathway that enables this vaccine to induce a CD8+ cytotoxic T-lymphocyte (CTL) response?

  1. The injected spike protein is taken up by antigen-presenting cells (APCs) and presented on MHC class II molecules.
  2. The vaccine mRNA is translated into spike protein within the host cell's cytoplasm, processed by the proteasome, and presented on MHC class I molecules. (correct answer)
  3. The lipid nanoparticle acts as a superantigen, directly and non-specifically activating a wide range of CD8+ T cells.
  4. The mRNA itself is recognized by pattern recognition receptors, leading to cytokine release that directly primes naive CD8+ T cells without antigen presentation.
Explanation: CD8+ CTLs recognize antigens presented on MHC class I molecules. The MHC class I pathway is responsible for presenting endogenous antigens—proteins that are synthesized within a cell. In the case of an mRNA vaccine, the host's own cellular machinery (ribosomes) translates the vaccine mRNA into the viral spike protein. This protein is then in the cytoplasm, where it is processed by the proteasome, transported into the endoplasmic reticulum by TAP, and loaded onto MHC class I molecules for presentation on the cell surface. This mimics a natural viral infection and allows for the activation of antigen-specific CD8+ T cells. A: Presentation on MHC class II activates CD4+ helper T cells, not CD8+ CTLs. This happens with exogenous antigens (like in a subunit vaccine). C: Superantigens cause polyclonal T-cell activation, which is not the specific, targeted response induced by this vaccine. D: While PRR recognition is important for the innate immune activation that helps drive the adaptive response, CD8+ T cells still require specific antigen presentation via MHC class I for priming.

Question 4

A 30-year-old patient presents with fever and a sore throat. Rapid testing confirms an infection with Pathogen X. Lab records show the patient had a documented infection with the same pathogen 5 years prior. Analysis of the patient's serum reveals a high titer of high-affinity IgG antibodies against Pathogen X within 3 days of symptom onset, with very low levels of IgM.

Which of the following best explains the rapid and robust antibody response observed in this patient?

  1. Activation of naive B cells that rapidly undergo class switching and somatic hypermutation.
  2. Reactivation of long-lived plasma cells that were generated during the primary infection and reside in the bone marrow.
  3. Antigen-driven activation and differentiation of memory B cells into plasma cells. (correct answer)
  4. A T-cell independent response to polysaccharide antigens on the surface of Pathogen X.
Explanation: The scenario describes a classic secondary (anamnestic) immune response, characterized by a rapid onset, high titer of IgG, and high antibody affinity. This response is mediated by the activation of memory B cells established during the primary infection. Upon re-exposure to the antigen, these memory B cells rapidly differentiate into plasma cells, which produce large quantities of high-affinity, class-switched antibodies (IgG in this case). A: Activation of naive B cells characterizes a primary response, which is slower, has an initial IgM phase, and produces lower-affinity antibodies. B: Long-lived plasma cells do contribute to baseline antibody levels but are not responsible for the rapid increase in titer upon re-exposure; that is the role of memory B cells differentiating into new plasma cells. D: A T-independent response would primarily generate IgM, would not show high affinity, and would not establish robust memory, which contradicts the patient's presentation.

Question 5

A lab develops a novel nanoparticle-based vaccine. To assess its ability to induce memory, they immunize mice and analyze their spleen and bone marrow 8 weeks later. Which cell population, if found in high numbers in the bone marrow, would be the best indicator of a successful, long-term humoral memory response?

  1. Antigen-specific naive B cells.
  2. Short-lived IgM-secreting plasma cells.
  3. Antigen-specific central memory T cells.
  4. Antigen-specific, class-switched, long-lived plasma cells. (correct answer)
Explanation: Long-term protective humoral immunity is primarily maintained by two key cell populations generated during a T-dependent immune response: memory B cells and long-lived plasma cells. While memory B cells are critical for a rapid secondary response, the steady-state level of protective antibodies in the serum is maintained by long-lived plasma cells. After the germinal center reaction, these cells migrate to survival niches, predominantly in the bone marrow, where they can continue to secrete high-affinity, class-switched (e.g., IgG) antibodies for years or even a lifetime. Therefore, their presence in the bone marrow is a direct and crucial indicator of durable humoral memory. A: Naive B cells are precursors and do not indicate a memory response. B: Short-lived plasma cells are found early in the response, often in the spleen, and do not persist. C: Central memory T cells are crucial for memory but are part of the cellular arm and do not themselves produce antibodies; they are also more typically found in secondary lymphoid organs like the spleen, not preferentially in the bone marrow.

Question 6

An individual born in 1970 was infected with influenza A strain 'X'. In 2020, they are exposed to a novel influenza A strain 'Y', which shares some conserved internal epitopes with strain X but has significantly different surface glycoproteins (hemagglutinin and neuraminidase).

Based on the principle of original antigenic sin, which outcome is most likely for this individual's immune response to strain Y?

  1. A de novo primary immune response will be mounted against strain Y, with no influence from the previous infection with strain X.
  2. The response will be dominated by reactivated memory B cells from the strain X infection, producing antibodies that preferentially bind to conserved epitopes, potentially hindering the development of a novel response to strain Y's unique surface antigens. (correct answer)
  3. The individual will have complete sterilizing immunity to strain Y due to cross-reactive memory T cells recognizing the conserved internal epitopes.
  4. The response will consist exclusively of high-affinity antibodies against the novel surface glycoproteins of strain Y, as the immune system prioritizes new antigenic challenges.
Explanation: Original antigenic sin (or antigenic imprinting) describes the phenomenon where the immune system's response to a new variant of a pathogen is biased by the memory of the first encounter with a related strain. The immune system preferentially activates the pre-existing memory cells. In this case, memory B cells specific for the conserved epitopes shared between X and Y will be rapidly activated. This can be beneficial but can also impair the development of a robust, high-affinity response against the new, unique epitopes of strain Y, potentially leading to a suboptimal response. A: This is incorrect; immunological memory from the first infection will certainly influence the response. C: While cross-reactive T cells can contribute to protection, they are unlikely to provide complete sterilizing immunity, especially when the surface antigens are different. D: This is the opposite of what original antigenic sin describes; the pre-existing memory response often dominates over a new primary response.

Question 7

Two new vaccines are developed against an intracellular virus that establishes a latent infection. Vaccine A is a live-attenuated viral vaccine. Vaccine B is a recombinant subunit vaccine consisting of a key viral surface protein formulated with an alum-based adjuvant.

Which vaccine is more likely to generate a protective immune response that effectively clears latently infected host cells upon viral reactivation, and why?

  1. Vaccine A, because the attenuated virus replicates intracellularly, leading to endogenous antigen presentation on MHC class I and robust activation of cytotoxic CD8+ T cells. (correct answer)
  2. Vaccine B, because the purified subunit protein is highly immunogenic and elicits a higher titer of neutralizing antibodies compared to the live virus.
  3. Vaccine A, because live-attenuated vaccines are known to induce a stronger Th2 response, which is critical for controlling intracellular pathogens.
  4. Vaccine B, because alum adjuvants are specifically designed to promote MHC class I presentation and the generation of cytotoxic T lymphocytes.
Explanation: Clearing latently infected cells requires cytotoxic CD8+ T lymphocytes (CTLs), which recognize viral peptides presented on MHC class I molecules. Live-attenuated vaccines involve intracellular replication of the virus, causing viral proteins to be synthesized within the host cell (endogenous antigens). These proteins are processed and presented on MHC class I, leading to strong activation of virus-specific CD8+ T cells. Subunit vaccines present exogenous antigens that are primarily processed through the MHC class II pathway, leading to a strong CD4+ T cell and B cell (antibody) response, but a much weaker CD8+ T cell response. B: While Vaccine B might elicit high antibody titers, antibodies are ineffective against intracellular pathogens once infection is established. C: Live-attenuated vaccines typically induce a balanced Th1/Th2 response, with a strong Th1 component critical for cell-mediated immunity, not a stronger Th2 response. D: Alum, a common adjuvant in subunit vaccines, primarily promotes a Th2-type response and is not effective at inducing strong CTL responses.

Question 8

Immunity conferred by the live-attenuated measles vaccine is typically lifelong, whereas immunity from the acellular pertussis (aP) subunit vaccine wanes over several years, necessitating boosters.

Which factor is the most significant immunological reason for the longer duration of memory from the measles vaccine compared to the aP vaccine?

  1. The measles virus has a more complex antigenic structure than the components in the acellular pertussis vaccine.
  2. The aP vaccine contains an alum adjuvant that actively suppresses the formation of long-lived plasma cells.
  3. The measles vaccine is administered later in childhood when the immune system is more mature and capable of lifelong memory.
  4. The limited replication of the attenuated measles virus provides prolonged antigenic stimulation and a more robust innate immune signal. (correct answer)
Explanation: When comparing vaccine-induced immunity duration, focus on how different vaccine types stimulate the immune system. Live-attenuated vaccines contain weakened but replicating pathogens, while subunit vaccines contain only specific pathogen components. The measles vaccine's superior longevity stems from the attenuated virus's ability to replicate in limited amounts within your body. This controlled replication provides two critical advantages: prolonged antigen presentation over days to weeks (rather than hours) and robust activation of innate immunity through pattern recognition receptors that detect replicating viruses. This combination drives stronger germinal center responses in lymph nodes, producing more long-lived plasma cells and memory B cells that persist for decades. Option A incorrectly suggests antigenic complexity determines memory duration. While measles virus is complex, the acellular pertussis vaccine contains multiple antigens too, yet immunity still wanes. Option B mischaracterizes alum adjuvant's function—alum enhances immune responses and doesn't suppress plasma cell formation, though it's less potent than the innate signals from replicating viruses. Option C focuses on timing, but vaccination age isn't the determining factor here; infants can develop lifelong immunity to live vaccines, and adults receiving aP boosters still experience waning immunity. The key difference is replication: live-attenuated vaccines act like mild, controlled infections that provide sustained antigenic stimulation and strong danger signals, while subunit vaccines deliver a brief antigenic pulse without replication-associated immune activation. Study tip: Remember that live-attenuated vaccines generally provide longer immunity than inactivated or subunit vaccines because replication mimics natural infection's immune stimulation patterns.

Question 9

Screening of two asymptomatic individuals for Hepatitis B virus (HBV) markers yields different results. Individual X is positive only for anti-HBs antibodies. Individual Y is positive for both anti-HBs and anti-HBc (total) antibodies. What is the most likely immunological history for each individual?

  1. X has been vaccinated against HBV; Y has resolved a past infection. (correct answer)
  2. X has a chronic HBV infection; Y has resolved a past infection.
  3. X has resolved a past infection; Y has been vaccinated against HBV.
  4. X has an acute HBV infection; Y has a chronic HBV infection.
Explanation: When interpreting hepatitis B serology, you need to understand what each antibody marker tells you about a person's exposure history. Anti-HBs antibodies indicate immunity to hepatitis B, while anti-HBc antibodies reveal past or ongoing infection with the actual virus. Individual X shows only anti-HBs positivity, which is the classic pattern for vaccination. The hepatitis B vaccine contains only surface antigen (HBsAg), so vaccinated individuals develop anti-HBs antibodies but never produce anti-HBc antibodies because they were never exposed to the core antigen of live virus. Individual Y has both anti-HBs and anti-HBc antibodies, indicating resolved natural infection. When someone recovers from actual hepatitis B infection, their immune system has been exposed to all viral components, producing both anti-HBc (from core antigen exposure) and anti-HBs (indicating clearance and immunity). Answer A correctly identifies these patterns. Answer B incorrectly suggests X has chronic infection, but chronic patients would be HBsAg positive, not anti-HBs positive. Answer C reverses the interpretations - natural infection always produces anti-HBc, while vaccination does not. Answer D describes active infections, but both individuals are asymptomatic with anti-HBs positivity indicating immunity, not active disease. Remember this key distinction: anti-HBs alone suggests vaccination, while anti-HBs plus anti-HBc indicates recovered natural infection. Anti-HBc is your marker for "this person encountered real virus," while isolated anti-HBs typically means "this person was vaccinated."

Question 10

A patient receives human rabies immunoglobulin (HRIG) and the rabies vaccine series after being bitten by a potentially rabid animal. Which statement accurately distinguishes the two components of this post-exposure prophylaxis?

  1. HRIG provides long-term active immunity, while the vaccine provides immediate but temporary passive immunity.
  2. Both HRIG and the vaccine stimulate the patient's immune system to produce memory B and T cells.
  3. HRIG provides immediate passive immunity by supplying pre-formed antibodies, while the vaccine induces long-term active immunity. (correct answer)
  4. HRIG consists of an inactivated virus that primes the immune system, while the vaccine consists of neutralizing antibodies.
Explanation: This scenario describes a combination of passive and active immunization. The human rabies immunoglobulin (HRIG) is a preparation of pre-formed antibodies against the rabies virus. It provides immediate, artificial passive immunity to neutralize the virus before it can infect the nervous system. However, this protection is temporary as the antibodies are eventually degraded. The rabies vaccine is an inactivated virus that stimulates the patient's own immune system to produce its own antibodies and memory cells, a process known as artificial active immunity. This response takes time to develop but provides long-lasting protection. A: This reverses the roles of the two components. B: Only the vaccine stimulates the patient's own adaptive immune response to create memory. HRIG does not. D: This incorrectly describes the composition of HRIG and the vaccine.

Question 11

A vaccine against Streptococcus pneumoniae for infants consists of capsular polysaccharides conjugated to a carrier protein, such as a diphtheria toxoid. What is the primary immunological advantage of this conjugation?

  1. The protein carrier acts as a potent adjuvant, nonspecifically enhancing the innate immune response to the polysaccharide.
  2. The conjugation converts the T-independent polysaccharide antigen into a T-dependent antigen, enabling the generation of B-cell memory. (correct answer)
  3. The protein carrier allows the polysaccharide to be processed and presented via the MHC class I pathway, inducing a cytotoxic T-cell response.
  4. The polysaccharide increases the immunogenicity of the protein carrier, leading to better protection against diphtheria.
Explanation: Polysaccharides are T-independent (TI) antigens. They can activate B cells directly without T-cell help, but this response is weak, primarily IgM, and does not generate immunological memory or undergo affinity maturation. This is particularly true in infants, whose immune systems respond poorly to TI antigens. By covalently linking the polysaccharide (a hapten in this context) to a protein carrier (like diphtheria toxoid), the B cell that recognizes the polysaccharide internalizes the entire conjugate. It then processes and presents peptides from the protein carrier on its MHC class II molecules to carrier-specific helper T cells. These T cells then provide help (e.g., via CD40L and cytokines) to the B cell, allowing it to undergo class switching, affinity maturation, and differentiation into memory B cells. A: While the carrier may have some adjuvant properties, its main role is to engage T-cell help. C: This pathway is for endogenous antigens and leads to CD8+ responses, which is not the goal for an extracellular encapsulated bacterium. D: The goal is to enhance the response to the polysaccharide, not the carrier protein.

Question 12

To achieve herd immunity for a highly contagious respiratory virus with a basic reproduction number (R₀) of 12, a community vaccination program is initiated. Assuming the vaccine is 90% effective at preventing transmission, what is the approximate minimum proportion of the total population that must be vaccinated?

  1. 85%
  2. 92%
  3. 95%
  4. 100% (correct answer)
Explanation: This is a multi-step problem.
  1. Calculate the herd immunity threshold (HIT) using the formula HIT = 1 - (1/R₀). Here, HIT = 1 - (1/12) ≈ 1 - 0.083 = 0.917, or 91.7%. This is the proportion of the population that must be immune to stop transmission.
  2. Account for vaccine effectiveness. The vaccine is only 90% effective. Let V be the proportion of the population that needs to be vaccinated. The proportion of the population that becomes immune through vaccination is V * 0.90. We need this proportion to equal the HIT.
  3. Set up the equation: V * 0.90 = 0.917.
  4. Solve for V: V = 0.917 / 0.90 ≈ 1.019. Since it is not possible to vaccinate more than 100% of the population, this calculation shows that even with 100% vaccination coverage, the herd immunity threshold cannot be reached with a vaccine of this effectiveness against a pathogen this contagious. Therefore, the minimum proportion to get as close as possible is 100%.
A, B, C: These are plausible but incorrect calculations. 92% (B) is the herd immunity threshold itself, but this does not account for the vaccine's imperfect effectiveness. A student who forgets to account for effectiveness might choose B.

Question 13

The measles, mumps, and rubella (MMR) vaccine is typically administered at 12-15 months of age. What is the primary immunological reason for delaying this live-attenuated vaccine administration, rather than giving it at birth?

  1. The infant's adaptive immune system is functionally immature at birth and cannot generate memory cells.
  2. Maternally derived IgG antibodies present in the infant can neutralize the vaccine virus, preventing effective replication and immune response. (correct answer)
  3. The adjuvant components of the MMR vaccine are known to be toxic to neonates but are safe for older infants.
  4. The infant's innate immune system is overactive at birth, which would destroy the attenuated virus too quickly for memory to form.
Explanation: The main reason for the timing of the MMR vaccine is the presence of maternal antibodies. IgG antibodies are transported across the placenta during pregnancy, providing the infant with passive immunity for the first several months of life. If the live-attenuated MMR vaccine is given during this time, these maternal antibodies will bind to and neutralize the vaccine virus. This prevents the virus from replicating sufficiently to stimulate the infant's own robust, long-lasting active immune response and memory formation. The vaccine is delayed until these maternal antibody levels have waned to a point where they no longer interfere. A: While the infant immune system is still developing, it is capable of responding to vaccines (e.g., Hepatitis B is given at birth). The primary issue for MMR is interference, not incompetence. C: The MMR vaccine does not contain an adjuvant. D: The infant innate immune system is generally considered less robust than an adult's, not overactive.

Question 14

Two new vaccines are developed against an intracellular virus that establishes a latent infection. Vaccine A is a live-attenuated viral vaccine. Vaccine B is a recombinant subunit vaccine consisting of a key viral surface protein formulated with an alum-based adjuvant.

Which vaccine is more likely to generate a protective immune response that effectively clears latently infected host cells upon viral reactivation, and why?

  1. Vaccine A, because the attenuated virus replicates intracellularly, leading to endogenous antigen presentation on MHC class I and robust activation of cytotoxic CD8+ T cells. (correct answer)
  2. Vaccine B, because the purified subunit protein is highly immunogenic and elicits a higher titer of neutralizing antibodies compared to the live virus.
  3. Vaccine A, because live-attenuated vaccines are known to induce a stronger Th2 response, which is critical for controlling intracellular pathogens.
  4. Vaccine B, because alum adjuvants are specifically designed to promote MHC class I presentation and the generation of cytotoxic T lymphocytes.
Explanation: Clearing latently infected cells requires cytotoxic CD8+ T lymphocytes (CTLs), which recognize viral peptides presented on MHC class I molecules. Live-attenuated vaccines involve intracellular replication of the virus, causing viral proteins to be synthesized within the host cell (endogenous antigens). These proteins are processed and presented on MHC class I, leading to strong activation of virus-specific CD8+ T cells. Subunit vaccines present exogenous antigens that are primarily processed through the MHC class II pathway, leading to a strong CD4+ T cell and B cell (antibody) response, but a much weaker CD8+ T cell response. B: While Vaccine B might elicit high antibody titers, antibodies are ineffective against intracellular pathogens once infection is established. C: Live-attenuated vaccines typically induce a balanced Th1/Th2 response, with a strong Th1 component critical for cell-mediated immunity, not a stronger Th2 response. D: Alum, a common adjuvant in subunit vaccines, primarily promotes a Th2-type response and is not effective at inducing strong CTL responses.

Question 15

To achieve herd immunity for a highly contagious respiratory virus with a basic reproduction number (R₀) of 12, a community vaccination program is initiated. Assuming the vaccine is 90% effective at preventing transmission, what is the approximate minimum proportion of the total population that must be vaccinated?

  1. 85%
  2. 92%
  3. 95%
  4. 100% (correct answer)
Explanation: This is a multi-step problem.
  1. Calculate the herd immunity threshold (HIT) using the formula HIT = 1 - (1/R₀). Here, HIT = 1 - (1/12) ≈ 1 - 0.083 = 0.917, or 91.7%. This is the proportion of the population that must be immune to stop transmission.
  2. Account for vaccine effectiveness. The vaccine is only 90% effective. Let V be the proportion of the population that needs to be vaccinated. The proportion of the population that becomes immune through vaccination is V * 0.90. We need this proportion to equal the HIT.
  3. Set up the equation: V * 0.90 = 0.917.
  4. Solve for V: V = 0.917 / 0.90 ≈ 1.019. Since it is not possible to vaccinate more than 100% of the population, this calculation shows that even with 100% vaccination coverage, the herd immunity threshold cannot be reached with a vaccine of this effectiveness against a pathogen this contagious. Therefore, the minimum proportion to get as close as possible is 100%.
A, B, C: These are plausible but incorrect calculations. 92% (B) is the herd immunity threshold itself, but this does not account for the vaccine's imperfect effectiveness. A student who forgets to account for effectiveness might choose B.

Question 16

The measles, mumps, and rubella (MMR) vaccine is typically administered at 12-15 months of age. What is the primary immunological reason for delaying this live-attenuated vaccine administration, rather than giving it at birth?

  1. The infant's adaptive immune system is functionally immature at birth and cannot generate memory cells.
  2. Maternally derived IgG antibodies present in the infant can neutralize the vaccine virus, preventing effective replication and immune response. (correct answer)
  3. The adjuvant components of the MMR vaccine are known to be toxic to neonates but are safe for older infants.
  4. The infant's innate immune system is overactive at birth, which would destroy the attenuated virus too quickly for memory to form.
Explanation: The main reason for the timing of the MMR vaccine is the presence of maternal antibodies. IgG antibodies are transported across the placenta during pregnancy, providing the infant with passive immunity for the first several months of life. If the live-attenuated MMR vaccine is given during this time, these maternal antibodies will bind to and neutralize the vaccine virus. This prevents the virus from replicating sufficiently to stimulate the infant's own robust, long-lasting active immune response and memory formation. The vaccine is delayed until these maternal antibody levels have waned to a point where they no longer interfere. A: While the infant immune system is still developing, it is capable of responding to vaccines (e.g., Hepatitis B is given at birth). The primary issue for MMR is interference, not incompetence. C: The MMR vaccine does not contain an adjuvant. D: The infant innate immune system is generally considered less robust than an adult's, not overactive.

Question 17

A vaccine against Streptococcus pneumoniae for infants consists of capsular polysaccharides conjugated to a carrier protein, such as a diphtheria toxoid. What is the primary immunological advantage of this conjugation?

  1. The protein carrier acts as a potent adjuvant, nonspecifically enhancing the innate immune response to the polysaccharide.
  2. The conjugation converts the T-independent polysaccharide antigen into a T-dependent antigen, enabling the generation of B-cell memory. (correct answer)
  3. The protein carrier allows the polysaccharide to be processed and presented via the MHC class I pathway, inducing a cytotoxic T-cell response.
  4. The polysaccharide increases the immunogenicity of the protein carrier, leading to better protection against diphtheria.
Explanation: Polysaccharides are T-independent (TI) antigens. They can activate B cells directly without T-cell help, but this response is weak, primarily IgM, and does not generate immunological memory or undergo affinity maturation. This is particularly true in infants, whose immune systems respond poorly to TI antigens. By covalently linking the polysaccharide (a hapten in this context) to a protein carrier (like diphtheria toxoid), the B cell that recognizes the polysaccharide internalizes the entire conjugate. It then processes and presents peptides from the protein carrier on its MHC class II molecules to carrier-specific helper T cells. These T cells then provide help (e.g., via CD40L and cytokines) to the B cell, allowing it to undergo class switching, affinity maturation, and differentiation into memory B cells. A: While the carrier may have some adjuvant properties, its main role is to engage T-cell help. C: This pathway is for endogenous antigens and leads to CD8+ responses, which is not the goal for an extracellular encapsulated bacterium. D: The goal is to enhance the response to the polysaccharide, not the carrier protein.

Question 18

Following recovery from a resolved acute viral infection, which population of memory T cells is primarily responsible for long-term surveillance by circulating through secondary lymphoid organs and initiating a rapid proliferative response upon secondary exposure?

  1. Effector memory T cells (Tₑₘ) located in peripheral non-lymphoid tissues.
  2. Tissue-resident memory T cells (Tₑₘ) that remain at the site of the initial infection.
  3. Central memory T cells (Tₑₘ) that express CCR7 and L-selectin. (correct answer)
  4. Recently activated effector T cells that have not yet undergone contraction.
Explanation: Immunological memory in the T-cell compartment is maintained by distinct subsets. Central memory T cells (TCM) are characterized by their expression of the lymph node homing receptors CCR7 and L-selectin (CD62L). This allows them to reside in and recirculate between secondary lymphoid organs (like lymph nodes and spleen). Upon re-encountering their cognate antigen, they exhibit a high proliferative capacity, rapidly expanding to generate a large pool of new effector cells. A: Effector memory T cells (TEM) lack CCR7 and circulate through peripheral tissues, poised for immediate effector function rather than proliferation in lymph nodes. B: Tissue-resident memory T cells (TRM) are non-circulating and provide a first line of defense at barrier surfaces. D: Recently activated effector T cells are part of the primary response and most will die by apoptosis during the contraction phase; they are not the long-lived memory population.

Question 19

A researcher is developing a subunit vaccine against an intracellular bacterium and wants to elicit a strong Th1-mediated cellular immune response. They are considering using aluminum salts (alum) or monophosphoryl lipid A (MPL) as an adjuvant.

Which adjuvant would be more suitable for the researcher's goal, and why?

  1. MPL, because it is a Toll-like receptor 4 (TLR4) agonist that preferentially drives the differentiation of T helper cells towards a Th1 phenotype. (correct answer)
  2. Alum, because it creates a depot effect that ensures prolonged antigen release, which is optimal for Th1 responses.
  3. Alum, because it activates the NLRP3 inflammasome, which results in the production of cytokines like IL-12 that are critical for Th1 polarization.
  4. MPL, because as a lipid-based adjuvant, it helps deliver the antigen directly into the MHC class I pathway for CTL activation.
Explanation: When you encounter questions about adjuvant selection for vaccines, focus on the specific immune response needed. Intracellular bacteria require Th1-mediated cellular immunity, which involves specific cytokines and signaling pathways that different adjuvants promote to varying degrees. MPL (monophosphoryl lipid A) is the optimal choice because it acts as a TLR4 agonist that specifically promotes Th1 differentiation. When MPL binds to TLR4 on antigen-presenting cells, it triggers signaling pathways that lead to IL-12 and IFN-γ production—the key cytokines that drive naive T helper cells toward the Th1 phenotype. This creates the cellular immune response needed to combat intracellular pathogens. Looking at the incorrect options: Option B incorrectly suggests alum is better due to depot effects, but while alum does create antigen depots, this mechanism doesn't specifically promote Th1 responses—alum actually favors Th2 responses. Option C contains a factual error: although alum does activate the NLRP3 inflammasome, this leads to IL-1β production, not IL-12, and ultimately drives Th2 rather than Th1 polarization. Option D misunderstands MPL's mechanism—while MPL is lipid-based, it doesn't directly deliver antigens into the MHC class I pathway; instead, it works through TLR4 signaling to influence T helper cell differentiation. For microbiology exams, remember this pattern: alum promotes Th2 responses (good for extracellular pathogens), while TLR agonists like MPL promote Th1 responses (essential for intracellular pathogens). Match the adjuvant's immunological profile to the pathogen type and required immune response.

Question 20

A potential complication of using common viral vectors, such as adenovirus serotype 5 (Ad5), for vaccines is pre-existing immunity to the vector in the human population. How would high titers of pre-existing neutralizing anti-Ad5 antibodies most likely affect the outcome of vaccination with an Ad5-vectored vaccine?

  1. It would enhance vaccine immunogenicity by forming immune complexes that are more readily taken up by antigen-presenting cells.
  2. It would cause the vaccine vector to integrate into the host genome, leading to a risk of insertional mutagenesis.
  3. It would lead to rapid clearance of the vaccine vector before it can transduce host cells, resulting in reduced antigen expression and a weaker immune response. (correct answer)
  4. It would shift the immune response from the intended antigen to the vector itself, but the overall magnitude of the response would be unchanged.
Explanation: Viral vector vaccines use a harmless virus (the vector) to deliver genetic material for a target antigen into host cells. If a person has pre-existing immunity to the vector (e.g., from a prior adenovirus infection), they will have circulating neutralizing antibodies against that vector. When the vaccine is administered, these antibodies will bind to the vector particles, leading to their opsonization and clearance by phagocytes. This prevents the vector from successfully entering host cells to deliver its genetic payload. The result is significantly reduced expression of the target antigen, leading to a much weaker or even non-existent primary immune response and poor memory formation. A: While some immune complexes can enhance uptake, in this context, neutralizing antibodies primarily prevent infection/transduction, which is a negative outcome. B: Adenovirus vectors used for vaccines are typically non-integrating. D: The response to the intended antigen would be significantly reduced in magnitude, not just shifted.